Nanobiotix has temporarily paused trading of its shares in Europe while it prices the €75 million stock offering it launched in the wake of new data on its Johnson & Johnson-partnered lung cancer prospect.
https://european-biotechnology.com/wp-content/uploads/2026/05/getty-images-PCcG8ouwzPQ-unsplash.jpg54648192Nick Paul Taylor/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngNick Paul Taylor2026-05-19 13:27:482026-05-19 13:27:48SERB to pay Hansa €110M upfront for EU rights to kidney transplant drug
Marc Clausse will take up his new role as Chief Commercial Officer at Santhera Pharmaceuticals (SIX: SANN) at the beginning of June. He succeeds Geert Jan van Daal, who is retiring.
https://european-biotechnology.com/wp-content/uploads/2026/05/eb.com_Marc_Clausse-_Santhera-scaled.jpg25602278Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2026-05-19 11:56:112026-05-19 11:56:11New CCO starts in June
Harbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform.
https://european-biotechnology.com/wp-content/uploads/2026/05/julia-taubitz-zc4em1u9_Fo-unsplash-scaled.jpg17072560Nick Paul Taylor/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngNick Paul Taylor2026-05-18 13:58:072026-05-18 13:58:07Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet
Dr Andrea Pfeifer, long-serving CEO and co-founder from AC Immune, has decided to retire. AC Immune’s Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.
https://european-biotechnology.com/wp-content/uploads/2026/05/tk.de_Andrea_Pfeifer_AC_Immune_Portrat.jpg15121345Maren Kühr/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngMaren Kühr2026-05-18 10:08:352026-05-18 10:08:35Co-founder and CEO steps down
With $55m in fresh capital, Ulm-based NVision is expanding its quantum technology platform from MRI sensing into quantum computing for drug development. The diagnostics company Abbott is the round’s anchor investor.
German Boehringer Ingelheim is doubling down on next-generation autoimmune therapies with a deal worth up to €407.5m for a preclinical Immunitas (USA) antibody programme. The agreement highlights the growing race for selective immune-cell depletion approaches — and adds another strategic win for Novartis-, Merck-, Bayer- and Evotec-backed Immunitas.
https://european-biotechnology.com/wp-content/uploads/2025/11/bic_ingelheim-e1762275566553.webp408728Georg Kääb/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngGeorg Kääb2026-05-13 13:51:482026-05-13 13:51:48Millions for Preclinical Immunology: Boehringer Teams Up with Immunitas
Isomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform.
https://european-biotechnology.com/wp-content/uploads/2026/05/getty-images-aTWKwJllPOA-unsplash-scaled.jpg14402560Nick Paul Taylor/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngNick Paul Taylor2026-05-13 12:42:322026-05-13 12:42:32Isomorphic Labs raises $2.1B for AI-enabled drug discovery drive
https://european-biotechnology.com/wp-content/uploads/2026/05/micheile-henderson-ZVprbBmT8QA-unsplash-scaled.jpg17072560Nick Paul Taylor/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngNick Paul Taylor2026-05-12 13:44:422026-05-12 13:44:42Infex raises £4.3M for anti-infective R&D ahead of Phase 2a data on lead asset
Days after J&J update, Nanobiotix pauses trading amid €75M stock offering
Latest NewsNanobiotix has temporarily paused trading of its shares in Europe while it prices the €75 million stock offering it launched in the wake of new data on its Johnson & Johnson-partnered lung cancer prospect.
Infex reports Phase IIa win for anti-Pseudomonas antibody
Latest NewsA new monoclonal antibody approach could add an infection-directed option to the changing treatment landscape for non-cystic fibrosis bronchiectasis.
SERB to pay Hansa €110M upfront for EU rights to kidney transplant drug
Latest NewsSERB Pharmaceuticals has agreed to pay Hansa Biopharma €110 million upfront for European rights to a conditionally approved kidney transplant drug.
New CCO starts in June
AppointmentsMarc Clausse will take up his new role as Chief Commercial Officer at Santhera Pharmaceuticals (SIX: SANN) at the beginning of June. He succeeds Geert Jan van Daal, who is retiring.
Harbour posts preclinical data on would-be rival to Eli Lilly’s $1.9B obesity bet
Latest NewsHarbour BioMed has published preclinical obesity data on a potential challenger to Eli Lilly’s bimagrumab discovered using its artificial intelligence-enabled platform.
Co-founder and CEO steps down
AppointmentsDr Andrea Pfeifer, long-serving CEO and co-founder from AC Immune, has decided to retire. AC Immune’s Board of Directors has appointed the Chair, Dr Martin Zügel, to serve as interim CEO while the ongoing search for a permanent successor continues.
$55m financing round for NVision
Latest NewsWith $55m in fresh capital, Ulm-based NVision is expanding its quantum technology platform from MRI sensing into quantum computing for drug development. The diagnostics company Abbott is the round’s anchor investor.
Millions for Preclinical Immunology: Boehringer Teams Up with Immunitas
Latest NewsGerman Boehringer Ingelheim is doubling down on next-generation autoimmune therapies with a deal worth up to €407.5m for a preclinical Immunitas (USA) antibody programme. The agreement highlights the growing race for selective immune-cell depletion approaches — and adds another strategic win for Novartis-, Merck-, Bayer- and Evotec-backed Immunitas.
Isomorphic Labs raises $2.1B for AI-enabled drug discovery drive
Latest NewsIsomorphic Labs has raised $2.1 billion (€1.8 billion) to further develop its artificial intelligence engine and advance drugs discovered using the platform.
Infex raises £4.3M for anti-infective R&D ahead of Phase 2a data on lead asset
Latest NewsInfex Therapeutics has raised £4.3 million (€4.95 million) to advance an anti-infective pipeline led by a midphase drug candidate.